From Medscape Oncology

Coverage from the

European Hematology Association 25^th Annual Congress (EHA) 2020

June 11 - 21, 2020; Virtual Meeting

Conference News

EHA 2020 Venetoclax Plus LDAC Tops LDAC Alone in AML
Medscape Medical News, June 29, 2020
EHA 2020 Ibrutinib-Venetoclax Produces High MRD-Negative Rates in CLL/SLL
Medscape Medical News, June 24, 2020
EHA 2020 Novel Drug Imetelstat Shows Transfusion Independence in MDS
Medscape Medical News, June 23, 2020
EHA 2020 Drug Shows 'Striking' Efficacy in Hereditary Bleeding Disorder
Medscape Medical News, June 18, 2020

EHA 2020 New Option for AL Amyloidosis: Daratumumab Added to CyBorD
Medscape Medical News, June 18, 2020
EHA 2020 Omitting Whole Body Irradiation Before HSCT: Trial Stopped Early
Medscape Medical News, June 15, 2020
EHA 2020 Three-Drug Combo Promising Against High-Risk CLL
Medscape Medical News, June 15, 2020
EHA 2020 Safe to Skip Radiotherapy With Negative PET in Hodgkin Lymphoma
Medscape Medical News, June 15, 2020

Popular News from EHA 2019

Only 1 Year of Tx:
Venetoclax/
Obinutuzumab Combo in CLL The combination has the benefit of a fixed-duration course of just 12 months compared to other treatment options that are taken for longer, or even indefinitely.
Medscape Medical News, Jun 18, 2019
Acalabrutinib Now Finding a Role in CLL, Shows Good Tolerability The second-generation BTK inhibitor shows good tolerability and improved progression-free survival when compared to standard approaches, paving a way for CLL as a new indication.
Medscape Medical News, Jun 28, 2019
Novel Drug Could Be 'Disease Modifying' in Sickle Cell Disease An investigational agent, the first-in-class drug voxelotor, is seen as potentially ‘disease-modifying' as it targets mechanisms that cause anemia.
Medscape Medical News, Jun 17, 2019

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Previous Coverage